摘要
目的:探讨采用R-CHOP方案治疗的弥漫大B细胞淋巴瘤(DLBCL)的免疫表型及临床参数与其预后的关系。方法采用免疫组化SP法,检测57例DLBCL中CD10、bcl-6、MUMl和CD5的表达,根据Hans分型将其分为GCB型和non-GCB型。结果 57例DLBCL中表达CD10、bcl-6、MUM1和CD5分别有9例(15.8%)、36例(63.2%)、34例(59.6%)、4例(7.0%);GCB型17例(29.8%)、non-GCB型40例(70.2%)。57例DLBCL中死亡19例,GCB型预后与non-GCB型相比差异无统计学意义(P=0.132);CD5阳性患者死亡率高,但与CD5阴性者相比差异无统计学意义(P=0.594)。Ⅲ~Ⅳ期和年龄>60岁DLBCL患者死亡率高(P=0.001、P=0.017)。结论应用R-CHOP方案治疗的DLBCL其预后与患者年龄和肿瘤临床分期有关,与Hans分型无关。
Objective To study the relationship between immunophenotyping ,clinical features and prognosis of diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP.Methods The expression of CD10,bcl-6,MUM1 and CD5 was detected by immunohistochemistry in 57 cases of DLBCL ,and the patients were divided into the GCB and non-GCB type according to Hans algorithm.Results In 57 patients,the positive rates of CD10,bcl-6,MUM1 and CD5 were 15.8%(9 cases)、63.2%(36 ca-ses)、59.6%(34 cases) and 7%(4 cases),respectively.In the 57 cases of DLBCI,17 belonged to germinal center B-cell sub-type ,40 cases were of non-germinal center B-cell subtype .19 cases died of disease in all patients ,clinical stage and age has a sig-nificant effect on prognosis (P=0.001 and 0.017,respectively),and there were no significant difference in prognosis between GCB,non-GCB type,CD5 positive and CD5 negative cases .Conclusion Prognosis of DLBCL treated with R-CHOP is related with age and clinical stage ,but not related with Hans typing .
出处
《实用癌症杂志》
2014年第8期1015-1017,共3页
The Practical Journal of Cancer
关键词
弥漫性大B细胞淋巴瘤
免疫分型
预后
Diffuse large B-cell lymphoma
Immunophenotyping
Prognosis
